IMMUTEP LTD-SP ADR

IMMP represents Immunoprecise Antibodies Ltd., a company focused on antibody discovery and development. It uses its proprietary B cell screening and AI-driven platform to identify therapeutic antibodies for pharmaceutical and biotechnology partners. The company also offers research services and develops its own pipeline candidates.

The latest price for IMMP is shown on the stock detail page above. Since prices change throughout each trading session, that display is the best source for the current quote. Investors can also check the intraday high, low, and volume from the same page for additional context.

Volatility for IMMP can be influenced by its small-cap status, limited trading volume, and sensitivity to news about its antibody programs, partnerships, or financing. The stock may experience larger percentage moves than broader market averages. The page's price history and 52-week range can help illustrate recent trading swings.

IMMP trades on the Nasdaq Capital Market under its ticker. Its average daily volume is typically lower than that of large-cap stocks, which can lead to wider bid-ask spreads and more price movement per trade. Current volume and liquidity figures are available on the quote page above.

Reviewing IMMP's quarterly and annual reports, including the income statement, balance sheet, and cash flow statement, provides the foundation. Important areas include revenue trends, research and development spending, operating losses, and cash reserves. These filings are available through the SEC's EDGAR system and the company's investor relations site.

IMMP's risks include the need for continued capital to fund research and development, reliance on collaboration partners, clinical or regulatory setbacks for its antibody candidates, and competition in the biotechnology sector. As a small-cap stock, it may also be subject to greater price volatility and lower liquidity than larger peers.